300049.SZ
300049.SZ
CNE100000KG1
FRMS CO., LTD
Loading chart...

Company Profile

Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company also engages in the research and development and sales of diagnostic equipment and related medical services. It offers FibroScan series of liver fibrosis diagnostic instruments; FibroMeter series of blood test analysis tools for evaluating chronic liver disease; and FibroView data management software. It provides digital health management services; compound turtle shell softening liver tablets; and prescription drugs. The company was formerly known as Inner Mongolia FuRui Pharmaceutical Limited Liability Company. Inner Mongolia Furui Medical Science Co., Ltd. was founded in 1998 and is headquartered in Beijing, China.

Related stocks

2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
9887.HK
9887.HK • China
LEADS BIOLABS-B
45.56 HKD
1.15B USD 1Y -37.5%
600645.SS
600645.SS • China
VCANBIO CELL & GENE ENG CORP LT
19.1 CNY
1.34B USD 1Y -22%
603229.SS
603229.SS • China
ZHEJIANG AUSUN PHARMACEUTICAL C
8.19 CNY
1.02B USD 1Y -19.8%
2157.HK
2157.HK • China
LEPU BIO
3.82 HKD
878.4M USD 1Y -47.2%
002287.SZ
002287.SZ • China
CHEEZHENGTTM
19.56 CNY
1.67B USD 1Y -24.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
64.6% p.a.
Max Drawdown (5Y)
-57.7%
Sharpe Ratio (5Y)
0.33
Beta Factor
-0.31
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 66.4 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (64.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -72.6% in the extended horizon.
ende